Loading
Every dated change on the records linked to Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Active surveillance if asymptomatic and stable; sirolimus for progressive or symptomatic disease; surgery or liver transplant for isolated hepatic disease.
Surveillance first, sirolimus for progression (ESMO Open).
Week-48 progression-free survival 50 percent with paclitaxel against 20 percent with oral etoposide, and 64 percent against 44 percent with bleomycin plus vincristine; both investigational arms were inferior and closed early.
Neuroendocrine cohort: about one in four responded, concentrated in high-grade disease; angiosarcoma cohort about one in four, mostly cutaneous scalp and face tumours; many other cohorts inactive.
Primary endpoint met: most patients progression-free at two months; responses mainly in cutaneous scalp and face disease.
Penel and colleagues, JCO, phase 2.
Léauté-Labrèze and colleagues, NEJM: serendipitous discovery.